Treventis CSO Mark Reed was in attendance at the 8th Neurodegenerative Drug Development Summit (previously known as World CNS) held in Boston, Massachusetts from Feb 25-27. Among the speakers were Dementia Discovery Fund (and past Treventis advisor) Barbara Tate. This year’s main topics were progress in biomarker technologies and gene therapy, as well as emergence of new targets.
Dr. Reed was thrilled to participate in this summit and learn more valuable insights into CNS drug development and the industry overall.